MIA's Dermatology services expanded
27 May 2016
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia. We now have five specialist dermatologists consulting from the Poche Centre:
- Associate Professor Pascale Guitera
- Dr Linda Martin
- Dr Erin Mullan
- Dr Hsien Herbert Chan
- Dr Annika Smith
Our areas of expertise include:
- Diagnosis of difficult melanocytic lesions
- Dysplastic naevus syndrome
- Lentigo maligna
- Amelanotic melanoma
- Nail pigmentation
- Mucosal pigmentation
- Management of cutaneous side effects of systemic targeted and immunotherapies for metastatic melanoma
- Pigmented lesions and melanoma in pregnancy
- Patient education on skin cancer prevention and melanoma patient support group
We also have state-of-the-art non-invasive diagnostic technology including:
- Advanced dermoscopy
- In-vivo confocal reflectance microscopy
- Total body photography
- Sequential dermoscopic imaging
- Optical coherence tomography
Contact Dermatology at MIA:
Suite 8, Level 3
The Poche Centre
40 Rocklands Rd
Wollstonecraft NSW 2065
T: 02 9911 7277
F: 02 9922 7220
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.